4.2 Article

Bushenshugan Formula Attenuates the Development of Lung Cancer by Inhibiting Epithelial-Mesenchymal Transition

期刊

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
卷 47, 期 5, 页码 1977-1988

出版社

KARGER
DOI: 10.1159/000491466

关键词

Bushenshugan Formula; Epithelial-mesenchymal transition; Lung cancer

资金

  1. National Natural Science Foundation of China [71673254, 81473497]
  2. National Key Research and Development Program of China-The construction and promotion of the demonstration system of based on telemedicine/Mhealth network [2017YFC0909900]
  3. Program of Science & Technology of Henan Province [201602037]
  4. Innovation Team of the First Affiliated Hospital of Zhengzhou University

向作者/读者索取更多资源

Background/Aims: BushenShugan Formula (BSF) is a traditional Chinese medicine that has therapeutic effects on middle-and late-stage lung adenocarcinoma in clinical application. It was reported that Bushen Chinese medicine suppressed the onset of pre-metastatic niches in a murine model of spontaneous lung metastasis. However, the mechanisms of BSF on human lung adenocarcinoma remain unknown. Methods: Cell proliferation was determined by CCK8 and colony formation. Cell apoptosis and cell cycle were detected by flow cytometry. Cancer stem cells properties were examined by spheroid body formation. The migration and invasion abilities were analyzed by wound healing assay and transwell invasion assay. The mRNA expressions were determined by qRT-PCR. Western blotting analysis showed the protein levels. Results: BSF was shown to inhibit the proliferation of A549 cells in time-and concentrationdependent manners. Colony formation assays also indicated the antiproliferative effect of BSF against A549 cells. Cellular mechanistic studies demonstrated that BSF arrested the cell cycle in G2/M phase and induced apoptosis. Importantly, BSF could inhibit the epithelial-mesenchymal transition(EMT) of A549 cells through PI3K/AKT/NF-kappa B pathway. Conclusions: BSF effectively inhibited tumour growth, suggesting that it is a promising anticancer treatment for further clinical development. (c) 2018 The Author(s) Published by S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据